Novo Nordisk Bets on Early-Stage Science to Offset a Bruising Year

Novo Nordisk gains ex-China rights to Hengrui's oral GLP-1/GIP candidate HRS-1596 for up to $2.6B, as its stock slides 23% this year.

Novo Nordisk is leaning on external science to shore up a pipeline that faces a looming patent cliff, even as its stock continues to slide. The Danish drugmaker has locked up worldwide rights outside mainland China to HRS-1596, an experimental obesity and type-2 diabetes treatment from China's Jiangsu Hengrui Pharmaceuticals.

The licensing pact carries a $300 million upfront payment and could swell to as much as $2.6 billion if development, regulatory and sales milestones are met. Hengrui would also collect tiered royalties on future net sales in the licensed territories, which exclude mainland China, Hong Kong, Macau and Taiwan. Closing is targeted for the fourth quarter of 2026, subject to US antitrust clearance and other customary conditions.

At the heart of the deal is a dual GLP-1/GIP receptor agonist designed for once-weekly oral dosing. Chinese regulators have already cleared the start of Phase 1 trials, though whether a weekly tablet can deliver the required efficacy and tolerability is precisely what the coming studies must establish.

A Pipeline Hedge as Semaglutid's Clock Ticks

The move speaks to the pressure building across the metabolic disease space. Novo Nordisk wants to move beyond its established injectables into oral treatments, and management has set a goal of launching at least five new products with meaningful commercial potential by 2030. That target matters because patent protection for semaglutid, the company's flagship asset, is expected to lapse in the US and Europe in the early 2030s.

BMO Capital's Evan Seigerman rates the shares "Market Perform" with a $47 price target. In his view, the transaction barely shifts the near-term competitive landscape given how early the licensed compound sits in development, but it hands the company a strategically valuable option for long-term product differentiation.

Fresh Data Aimed at Eli Lilly

Novo Nordisk is also working to defend its existing franchise with real-world evidence. A retrospective study of 636,525 adults with type-2 diabetes found that raising the semaglutid dose cut the risk of major cardiovascular events by 6 percent compared with switching patients to Eli Lilly's tirzepatid. The company released those findings yesterday.

The result lands amid an intensifying battle for market share in diabetes and obesity care, where investors increasingly question whether Novo Nordisk can hold its lead. The stock closed yesterday at EUR 33.77, down 0.9 percent on the day.

That cardiovascular data adds to a run of scientific wins. On September 21, the company published initial results from the Phase 3 REIMAGINE 5 trial, in which the CagriSema combination at a 1.0 mg / 1.0 mg dose produced an estimated average weight loss of 12.4 percent. Participants on 5 mg of tirzepatid recorded a 9.1 percent reduction. With those numbers, Novo Nordisk is trying to show that its next-generation candidates remain competitive in the race for efficacy, as physicians and payers pay growing attention to clinical superiority in complications such as vascular damage and heart attacks.

Widening the Technology Base

External deals have become a recurring theme. On Friday, Novo Nordisk secured rights to the PharmaShell platform technology from Sweden's Nanexa for up to five development programs spanning obesity, type-2 diabetes and cardiometabolic disease. The Hengrui agreement, announced yesterday, followed close behind.

Analysts Stay Cautious After the Slide

The market has yet to reward these operational moves. The shares have shed 23 percent since the start of the year, and institutional observers remain guarded despite the recent trial data and acquisitions. Deutsche Bank trimmed its price target to DKK 245 from DKK 265 on September 22, keeping a sell rating, while Bank of America Securities assigned a "Hold" rating on Friday. For investors, the central question is whether the reported clinical advantages will be enough to ease the competitive pressure in the cardiometabolic market over the longer haul.